Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1321-1340 of 3,900 trials

Systemic Lupus Erythematosus: Dapirolizumab Pegol Study

We are studying whether dapirolizumab pegol can improve symptoms in people with moderately to severely active systemic lupus erythematosus. This trial will also assess the safety of this new treatment when added to standard care.

Systemic Lupus Erythematosus6-12 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Meningococcal B Vaccine for Adults with Asplenia

We are studying the safety and immune response of the BEXSERO® vaccine in adults without a spleen. This trial compares their response to healthy individuals to ensure effective protection against meningococcal disease.

Splenectomy6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Hepatocellular Carcinoma: Atezolizumab-Bevacizumab with Bacterial Supplements

We are studying whether adding bacterial supplements to a combination of atezolizumab and bevacizumab helps patients with hepatocellular carcinoma who have not responded to first-line treatment. The trial also looks at the safety of this new approach.

Non-resectable Hepatocellular Carcinoma1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyOncology

Recurrent Low-Grade Serous Ovarian Cancer: Avutometinib and Defactinib Study

We are studying a new combination therapy for patients with recurrent low-grade serous ovarian cancer to see if it helps them live longer and improves their quality of life compared to standard treatments.

Recurrent Low-Grade Serous Ovarian Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncology

Antiplatelet Therapy Duration After TAVI

We are studying whether a shorter 3-month antiplatelet therapy is as effective as the standard 12-month therapy after TAVI. The goal is to see if it reduces complications and bleeding risks.

Aortic Stenosis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Pain Management in Dental Emergencies: Methoxyflurane Study

We are studying whether methoxyflurane can effectively reduce pain and anxiety in adults facing oral emergencies. This trial will help us understand its benefits compared to a placebo.

Dental Pain and Sensation Disorders1-2 yearsConfirmation phase (III)Standard MedicinesGynecology and ObstetricsOtolaryngologyPediatrics

Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease

We are studying the safety and effects of tolvaptan in infants and children with ARPKD. The trial aims to see if it helps reduce the need for kidney treatments.

Autosomal Recessive Polycystic Kidney DiseaseConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Zanidatamab for Advanced HER2-Positive Biliary Tract Cancer

We are studying whether zanidatamab combined with standard chemotherapy helps patients with advanced HER2-positive biliary tract cancer more than standard chemotherapy alone. This trial aims to evaluate its effectiveness and safety.

Biliary Tract CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Corticosteroids Detection in Anti-Doping Tests

We are studying how corticosteroids are excreted to improve their detection in anti-doping controls. This research aims to help ensure fair play in sports.

Healthy VolunteersSafety phase (I)Internal Medicine

Chronic Inflammatory Bowel Disease: Intravenous Lidocaine Study

We are investigating whether intravenous lidocaine can reduce abdominal pain in patients with chronic inflammatory bowel disease. Additionally, we will study how this treatment affects brain activity compared to healthy volunteers.

Inflammatory Bowel Disease3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Advanced Solid Tumors: GTAEXS617 Treatment Study

We are testing a new treatment called GTAEXS617 for patients with advanced solid tumors to see how safe it is and whether it can help fight the cancer. This study will look at the treatment alone and with standard therapies.

Ovarian Epithelial CancerColorectal AdenocarcinomaNon-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

MDMA-Assisted Therapy for Treatment-Resistant PTSD

We are studying whether MDMA-assisted therapy can improve symptoms of PTSD in individuals who have not responded to other treatments. This trial also looks at how well this therapy works in a hospital setting.

Posttraumatic Stress Disorder6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemotePsychiatry

HER3-Targeted Imaging with Patritumab Deruxtecan

We are studying the best dose of a new imaging agent for patients with tumors that express HER3. This research aims to improve how we visualize and understand tumor response to treatment.

EGFR Mutation Positive Advanced Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOncology

Crohn's Disease: Obefazimod Study

We are testing a new medication, obefazimod, for people with moderately to severely active Crohn's disease who haven't responded to other treatments. The study aims to see if it is more effective and safe compared to a placebo.

Crohn's Disease>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Severe Systemic Lupus Erythematosus: Obecabtagene Autoleucel Study

We are studying a new treatment for patients with severe, hard-to-treat systemic lupus erythematosus. The trial aims to evaluate its safety, tolerability, and early signs of effectiveness.

Severe Systemic Lupus ErythematosusSafety phase (I)No PlaceboInvestigational MedicinesInternal MedicineRheumatology

Acute Mesenteric Ischemia: Oral Antibiotics Study

We are investigating whether oral antibiotics can help reduce serious complications in patients with acute mesenteric ischemia. This study compares the effects of antibiotics to a placebo to see if they improve patient outcomes.

Acute Mesenteric Ischemia>2 yearsConfirmation phase (III)Standard MedicinesCardiologyGastroenterology

Psoriatic Arthritis: Tapering Immunosuppressive Therapy

We are studying whether reducing immunosuppressive medication helps adults with psoriatic arthritis maintain stable disease activity. The trial also looks at the safety of this approach.

Psoriatic Arthritis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineRheumatology

Primary Aldosteronism: [18F]CETO Imaging Study

We are investigating a new imaging method using [18F]CETO to better classify types of primary aldosteronism. This may help improve diagnosis and treatment for affected individuals.

Primary AldosteronismSafety phase (I)Efficacy phase (II)EndocrinologyInternal Medicine

Noncardiac Surgery: Noradrenaline Infusion Study

We are investigating if noradrenaline infusion is more effective than standard blood pressure management in preventing low blood pressure during noncardiac surgery. This study aims to improve patient safety and outcomes in the operating room.

Low Blood Pressure During Surgery>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyOtolaryngology

Ovarian Cancer: Niraparib Rechallenge Study

We are studying whether Niraparib can help ovarian cancer patients with oligometastatic progression after surgery live longer without their cancer worsening. The trial will also assess safety and various health indicators.

Ovarian Cancer with Oligometastatic Progression1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGynecology and ObstetricsOncology